Sep. 6, 2013, 4:42 PM
- Johnson & Johnson (JNJ) recalls 200k bottles of its Motrin Infants Drops formula due to the risk that they contain tiny particles of plastic.
- Although it's unclear if the recalled bottles actually contain the particles, which were found in a different product during the manufacturing process, the company decided to issue the recall because both products contain the same shipment of ibuprofen from a third-party supplier.
Sep. 6, 2013, 1:55 PM
- Johnson & Johnson (JNJ +0.7%) is making the rounds to companies that might be interested in buying its blood-testing division, which could fetch around $5B.
- JNJ's Ortho Clinical Diagnostics unit makes tests that can reveal a patient's blood type and screen for viruses like HIV and hepatitis C. It also makes tests that help diagnose a heart attack and assess damage to the heart.
- The testing business is part of a $46B world-wide market for in vitro diagnostics that is growing 6% - 7% a year.
- A potential deal could be wrapped up by as early as the year's end.
Sep. 4, 2013, 6:57 PM
- There's been no change in the list of top 10 holdings of Morningstar's Ultimate Stock Pickers so far this year, but one wonders about the fate of Microsoft (MSFT) after its much criticized purchase of Nokia's main handset business; it had been the top high-conviction holding in the group.
- The top 10 holdings: MSFT, GOOG, WFC, JNJ, BRK.B, AIG, PG, WMT, PEP, UPS.
- Among purchases during the most recent period, National Oilwell Varco (NOV) topped the top 10 list of high-conviction buys, followed by WFC, GM, SLB, INTC, AAPL, XOM, APA, CHRW, EMC.
Sep. 1, 2013, 3:18 PM
- Daiichi Sankyo's edoxaban meets its primary endpoint of non-inferiority to warfarin in a Phase 3 study of more than 8K patients with either acute symptomatic deep vein thrombosis, DVT, pulmonary embolism, or both.
- When administered after heparin therapy, edoxaban was just as effective at preventing new blood clots as warfarin and caused less bleeding.
- "Edoxaban will face intense competition when it reaches the market," one analyst tells Bloomberg, adding that if approved for both venous thromboembolism and atrial fibrillation, edoxaban could see sales of ¥40B by year-end 2018.
- Expected to face competition from edoxaban: Pfizer (PFE) and Bristol-Myers' (BMY) Eliquis, Boehringer Ingelheim's Pradaxa, and Johnson & Johnson (JNJ) and Bayer's (BAYZF.PK) Xarelto.
- See also: Goldman says edoxaban poses limited threat to Eliquis.
Aug. 29, 2013, 7:33 AM
Aug. 27, 2013, 4:54 PM
- Johnson & Johnson (JNJ) appoints Jesse Wu, worldwide chairman of its consumer segment, as chairman of Johnson & Johnson China, a new position that's part of JNJ's effort to increase sales and centralize corporate oversight.
- JNJ's three Chinese operations have been reporting to separate business heads in the U.S.
- Lynn Pendergrass, a Hewlett-Packard (HPQ) senior VP overseeing the printing and personal systems businesses for the Americas, will join JNJ, taking over Wu's job as head of the global consumer business.
Aug. 21, 2013, 5:08 AM
- Johnson & Johnson (JNJ -0.2%) has reportedly discussed paying over $3B to settle up to 11,500 U.S. lawsuits over its recalled ASR hip implants.
- J&J has already spent $993M on medical costs and telling patients and surgeons about the recall. The company has also suffered an $8.3M verdict in one trial but won another one.
- The result of seven product-liability trials between September and January would affect any deal.
- The chromium and cobalt implants have been blamed for pain, metal debris and replacement surgeries.
Aug. 19, 2013, 5:34 PM
- Johnson & Johnson (JNJ) says it's completed its acquisition of Aragon Pharmaceuticals, a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.
- Development of compounds from Aragon's androgen receptor antagonist program, including its lead androgen receptor signaling inhibitor, ARN-509, will be managed by JNJ's Janssen Research & Development.
Aug. 15, 2013, 4:10 PM
- C.R. Bard (BCR) is ordered to pay $250K to a woman who sued, claiming she suffered injuries from the company’s vaginal-mesh implant.
- The trial was the first of more than 5,000 claims over the devices, and now moves to the punitive-damages phase in Charleston, West Virginia.
- Patients claim the implants cause organ damage and make sexual intercourse painful when they erode.
- Johnson & Johnson (JNJ), Endo Health (ENDP) and Boston Scientific (BSX) all face similar claims that their implants, threaded in place through incisions, degrade and shrink over time.
- BCR -1.7% AH.
Aug. 12, 2013, 11:11 AM
- Royalty Pharma says that pursuant to its collaboration with Aisling Capital and Clarus Ventures, it has sold the two companies around 20% of its royalty interest in Ibrutinib it recently acquired from Quest Diagnostics (DGX -0.2%).
- In payment, its will receive a pro rata percentage of the $485M it paid to Quest for the royalty.
- Pharmacyclics (PCYC +0.1%) and Johnson & Johnson (JNJ +0.3%) subsidiary Janssen Pharmaceuticals filed Ibrutinib with the FDA in July 2013 for the treatment of lymphoma and relapsed/refractory chronic lymphocytic leukemia, and currently has received three of the eight Breakthrough Therapy Designations granted by the FDA to date in oncology.
Aug. 12, 2013, 4:03 AM
- The Department of Health & Human Services is investigating the use of anti-psychotic drugs to treat Medicaid recipients aged 17 and under amid concern that the medicines are being over-prescribed. HHS wants to tighten oversight across the nation.
- The probe focuses on the five largest Medicaid states: California, Florida, Illinois, New York and Texas, and covers a period from January-June 2011, when 84,654 children received treatment. Other than that, the most recent data seems to date back to 2008.
- Medicaid spends billions of dollars a year on the drugs, which include those made by AstraZeneca (AZN), Eli Lilly (LLY) and Johnson & Johnson (JNJ), as well as by Otsuka Holdings (OTSKF.OB), the provider of Abilify, the top prescription drug by revenues in the U.S.
Aug. 7, 2013, 9:38 AM
- Scientists have been finding increasing evidence of links between gum disease and a number of medical conditions, including diabetes, heart disease, pregnancy complications and even Alzheimer's disease.
- "There’s a substantial body of research that connects them, but we are a long way from demonstrating causation," says Ian Needleman, a professor at University College London. "Can there be smoke without fire?
- If scientists do find causation, companies that could benefit include Colgate (CL), Johnson & Johnson (JNJ) and Procter & Gamble (PG).
Jul. 31, 2013, 11:41 AM
Jul. 29, 2013, 9:44 AM
- Leerink upgrades Actavis (ACT +1.8%) to Outperform from Market Perform, dismissing "current overhangs" as "low grade earnings risks."
- Price target raised to $155 from $133
- ACT files ANDA for a generic version of Janssen's (JNJ +0.3%) Nucynta. Janssen and Grunenthal GMBH file suit to prevent commercialization.
- Recent ACT news: Q2 earnings summary.
Jul. 26, 2013, 1:49 PM
The FDA changes the label on Johnson & Johnson's (JNJ -0.3%) Nizoral tablets to warn consumers that the anti-fungal drug should not be the first line of treatment due to the risk of liver injury and adverse drug interactions. The EMA is recommending the suspension of oral treatments containing Nizoral's principal ingredient. Topical formulations of the drug have not been associated with liver damage.| Jul. 26, 2013, 1:49 PM | 1 Comment
Jul. 25, 2013, 10:47 AM"This has had an enormous impact," Johnson & Johnson's (JNJ -0.2%) head of global regulatory affairs says during a congressional briefing on the FDA's power to grant Breakthrough Therapy designation. Bloomberg highlights JNJ and Pharmacyclics' (PCYC +1%) recent NDA for ibrutinib and notes that, thanks to the new designation, the companies will likely get a response from the regulator two years ahead of schedule. | Jul. 25, 2013, 10:47 AM | 2 Comments